Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation
1 other identifier
interventional
100
1 country
1
Brief Summary
The purpose of this study was to evaluate the protective effect of dexmedetomidine on myocardial injury during liver transplantation
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2016
CompletedFirst Submitted
Initial submission to the registry
December 22, 2016
CompletedFirst Posted
Study publicly available on registry
January 6, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2017
CompletedJanuary 6, 2017
January 1, 2017
1 year
December 22, 2016
January 4, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Peri-operative mortality
through study completion, an average of 5 weeks
The incidence of cardiac complications
from anesthesia induction to 24 hours after operation
Secondary Outcomes (1)
Evidences of Clinically Definite Myocardial Injury Confirmed by Electrochemiluminescence
before skin incision, 0.5 hour min after anhepatic, 2 hours of neohepatic stage,the end of surgery,24 hours after operation
Other Outcomes (2)
Length of ICU stay
through study completion, an average of 5 days
length of stay
through study completion, an average of 6 weeks
Study Arms (2)
Dexmedetomidine Group
EXPERIMENTALDexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
Normal saline Group
PLACEBO COMPARATOREqual volume normal saline substitute for dexmedetomidine
Interventions
Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
Eligibility Criteria
You may qualify if:
- End stage liver disease scheduled for liver transplantation in Tianjin First Center Hospital
You may not qualify if:
- Pre-existing respiratory failure,renal failure,hepatic encephalopathy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
No.24 Fukang Road,Nankai District
Tianjin, Tianjin Municipality, 300192, China
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Wenli Yu,PhD ,Department of Anesthesiology,Tianjin First Center Hospital
Study Record Dates
First Submitted
December 22, 2016
First Posted
January 6, 2017
Study Start
October 1, 2016
Primary Completion
October 1, 2017
Study Completion
November 1, 2017
Last Updated
January 6, 2017
Record last verified: 2017-01
Data Sharing
- IPD Sharing
- Will not share